News

PharmExec1h
Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment
Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...
Metastatic Urothelial Carcinoma Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ ...
Aethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier® ...
PharmExec23h
LEAP-002 Study Shows Five Year Survival Consistency in Unresectable Liver Cancer
Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...
Targeted Oncology23h
Recent Clinical Advances: Key Trial Data in First-Line mTNBC
An expert discusses how emerging trial data, particularly from ASCENT-04, are reshaping first-line treatment strategies for PD-L1–positive metastatic triple-negative breast cancer (mTNBC) by ...